Functional MRI to Assess Brain Damage in Cardiac Arrest Patients

Cardiac Arrest Clinical Trial

Official title:

Assessment of Cerebral Microcirculation, Blood-brain Barrier, and Cerebral Oxygenation Damage in Patients With Cardiac Arrest Using Functional MRI

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05966389
• Other study ID #: 2023-6-21-8
• Status: Recruiting
• Start date: January 1, 2021
• Est. completion date: January 2024

Study information

• Verified date: July 2023
• Source: Capital Medical University
• Contact: Ziren Tang, Ph.D
• Phone: +86 010-85231530
• Email: tangziren1970[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a single-center, observational study. Patients after successful cardiopulmonary resuscitation (CPR) will be transferred to the emergency intensive care unit for further standardized management. After successful return of spontaneous circulation (ROSC) for 72h and hemodynamics remained stable for 24h, the post-resuscitated patients underwent functional magnetic resonance imaging (fMRI) examination. During the examination, the supervising physician accompanied the patient and monitored the patient's vital signs using a magnetic resonance monitoring system (Siemens Healthcare Prism, Germany). Patients who are on ventilators are mechanically ventilated using a magnetic ventilator (HAMILTON-MRI, USA). In additional to conventional sequences, fMRI is performed for diffusion-prepared pseudo-continuous arterial spin labeling (DP-pCASL) and blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI). These MRI sequences allow quantitative assessment of the patients' cerebral microcirculation, blood-brain barrier, and cerebral oxygenation status. Patients will be followed up for neurologic prognosis according to the Modified Rankin Scale (mRS) at 6 months after disease onset.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• age =18 years.
• sustained hemodynamic stability for =24h.
• the patients were unconscious and not able to obey verbal commands.
• Advanced life support and target temperature management within 6 hours of return of spontaneous circulation (ROSC).

Exclusion Criteria:

• Patients with hemodynamic instability.
• Patients who could not complete cranial MRI examination for special reasons.
• Patients during pregnancy.
• Patients who combined traumatic brain injury, stroke, cerebral hemorrhage and other diseases.
• Patients whose family members did not agree to be enrolled.

Related Conditions & MeSH terms

• Brain Injuries
• Cardiac Arrest
• Heart Arrest

Intervention

Other:
• No interventions
No interventions

Locations

Country	Name	City	State
China	Beijing chaoyang hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neurologic prognosis	Patients will be followed up for neurologic prognosis according to the Modified Rankin Scale (mRS) at 6 months after disease onset.	6 months